Which growth standards should be used to identify large- and small-for-gestational age infants of mothers with type 1 diabetes? A pre-specified analysis of the CONCEPTT trial

Claire L Meek (clm70@cam.ac.uk)
University of Cambridge  https://orcid.org/0000-0002-4176-8329

Rosa Corcoy
Hospital de la Santa Creu i Sant Pau Institut de Recerca

Elizabeth Asztalos
Sunnybrook Research Institute

Laura Caroline Kusinski
University of Cambridge

Esther Lopez
Hospital de la Santa Creu i Sant Pau Institut de Recerca

Denice S Feig
Lunenfeld-Tanenbaum Research Institute

Helen R Murphy
University of East Anglia Norwich Medical School

Research article

Keywords: Large-for-gestational-age, small for gestational age, macrosomia, birth-weight, diabetes, pregnancy, CONCEPTT, growth standards, INTERGROWTH, GROW

Posted Date: July 9th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-27918/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on January 29th, 2021. See the published version at https://doi.org/10.1186/s12884-021-03554-6.
Abstract

Background Offspring of women with type 1 diabetes are at increased risk of accelerated fetal growth which is associated with perinatal morbidity. Growth standards are used to identify large- or small- for gestational age (LGA, SGA) infants. Our aim was to examine which growth standards identify infants at risk of perinatal complications during the Continuous Glucose Monitoring in Type 1 Diabetes Pregnancy Trial (CONCEPTT).

Methods This was a pre-specified analysis of CONCEPTT involving 225 pregnant women from 31 international centres. Infants were weighed immediately at birth and GROW, INTERGROWTH and WHO centiles calculated. Unadjusted logistic regression identified the associations between different growth standards and perinatal outcomes including preterm delivery, Caesarean delivery, neonatal hypoglycaemia, hyperbilirubinaemia, respiratory distress, neonatal intensive care unit (NICU) admission and a composite neonatal outcome.

Results Accelerated fetal growth was common, with mean birthweight percentiles of 82.1, 85.7 and 63.9 and LGA rates of 62%, 67% and 30% using GROW, INTERGROWTH and WHO standards respectively. Corresponding rates of SGA were 2.2%, 1.3% and 8.9% respectively. All standards were associated with some but not all perinatal outcomes studied. Infants born >97.7th centile were at highest risk of complications.

Conclusions WHO standards underestimated birthweight centile. GROW and INTERGROWTH standards identified similar numbers of infants as LGA and SGA with GROW showing stronger associations with neonatal hypoglycaemia, hyperbilirubinaemia and NICU admission. Infants with suspected birthweight >97.7th centile according to any standard may require extra surveillance. Definitions of LGA and SGA should be re-evaluated in diabetic pregnancy.

Background

Birth weight is an important indicator of neonatal well-being. Infants who are small- or large-for-gestational-age (SGA or LGA; birth weight <10th or >90th percentile) experience higher risks of morbidity and mortality. Assessment of growth in offspring of mothers with type 1 diabetes (T1D) is vital as they are at high risk of accelerated growth resulting in perinatal complications. Recent data suggests that despite improvements in care, infants of women with T1D remain at high risk of LGA (rates ~50%) . LGA rates were also high in the CONCEPTT randomized controlled multicentre international trial of the use of continuous glucose monitoring (CGM) in comparison with capillary blood glucose monitoring in pregnant women with T1D. LGA rates were significantly reduced in infants of women who used CGM (53% Vs 69% in home blood glucose monitoring group), likely due to improved glycaemic control.

Currently there is controversy internationally about which growth standards to use. Customised (Gestation Related Optimum Weight; GROW) centiles were used in CONCEPTT for the comparison of
birthweight across international sites and diagnosis of LGA. GROW centiles are customised to maternal and neonatal factors including maternal ethnicity, height, weight, parity, neonatal sex and gestational age [7, 10]. Advocates of GROW suggest that customised centiles reduce over-investigation of normal fetuses and can more accurately predict stillbirth and perinatal mortality rates 9 10.

Other techniques based on data from the INTERGROWTH-21st study (20 486 infants across eight geographical areas) and the World Health Organisation (WHO) Multicentre Growth Reference Study (8500 infants across six geographical areas) 11 12 are used internationally. Both standards assume <3.5% of the variability in growth is due to differences in ethnicity and population when circumstances are optimal (e.g healthy, well-nourished mothers) 13. INTERGROWTH-21st standards focus on fetal growth and neonatal size at birth, while the WHO charts assess weight-for-age at 0-60 months 12.

Population studies comparing growth standards have focused on the identification of SGA in unselected antenatal populations 9 10 14. However, in infants of women with T1D, LGA is five times more common than in the background maternity population 5. Identification of these infants may improve outcomes by increasing surveillance and targeting interventions to those at highest risk 15. However, the optimal method for growth assessment in infants of women with T1D diabetes is unclear and thus our aim was to examine which of the growth standards identified infants at highest risk of perinatal complications.

Methods

The recruitment, rationale and methodology of CONCEPTT is described in detail elsewhere 6. In brief, women with T1D were recruited before or during pregnancy and randomized to real-time continuous glucose monitoring or capillary glucose monitoring alone. Women in the capillary glucose monitoring group also had short periods of masked continuous glucose monitoring, to allow comparison of glycaemic control between groups. Women were followed-up until delivery with collection of information about birth outcomes. Local policies in the study sites were used to determine the optimal timing and method of delivery.

Pre-specified neonatal outcomes for the CONCEPTT study included miscarriage, stillbirth, neonatal death, birth injury, shoulder dystocia, preterm delivery, neonatal hypoglycaemia requiring intravenous dextrose, hyperbilirubinaemia, respiratory distress syndrome, neonatal intensive care unit admission requiring a duration of at least 24 hours, total length of hospital stay, birthweight, macrosomia (birthweight ≥4 kg), LGA (>90th centile) and SGA (<10th centile) based on customised centiles. Definitions for CONCEPTT outcomes are given in Appendix S2 and were standardised across all the CONCEPTT sites. This data was collected using participant’s medical records. A composite neonatal endpoint incorporated pregnancy loss (miscarriage, stillbirth, or neonatal death), birth injury, neonatal hypoglycaemia, hyperbilirubinaemia, respiratory distress syndrome, or neonatal intensive care admission>24 hours. This pre-specified secondary analysis includes data from pregnant and pre-pregnant recruits who became pregnant during the 6-month pre-pregnancy trial and who gave birth to a liveborn infant. Therefore, in the current study, the
composite neonatal endpoint incorporated birth injury, neonatal hypoglycaemia, hyperbilirubinaemia, respiratory distress syndrome, or neonatal intensive care admission >24 hours but not pregnancy loss.

Calculation of Birth weight Centiles

Gestational age at delivery was based upon ultrasound measurements in early pregnancy (approximately 12 weeks). Maternal height and weight required for the GROW calculation was measured by trained staff at the baseline study visit. As the CONCEPTT study recruited women in early pregnancy, this was considered broadly similar to pre-pregnancy weight.

GROW centiles were calculated using version 8 (2017) of the GROW calculator using data about maternal self-reported ethnicity, parity, height, weight, gestational age at birth and neonatal sex. INTERGROWTH centiles were calculated using the windows app (available at https://intergrowth21.tghn.org/intergrowth-21st-applications/; accessed 31/03/2019) using information about infant sex, weight and age (0-60 months). WHO centiles were calculated using data about infant sex, weight and gestational age at birth using the igrowup package for Stata (available at http://www.who.int/childgrowth/software/en/; accessed 31/03/2019). Some studies have previously reported standard deviation (SD) based birthweight categorisation. To allow comparison between centile-based methods and SD-based methods, we also included SD-based definitions for LGA (+1 and 2 SDs) using methods which were commonly used in the literature. Calculation of SGA using definitions <5th and <2.5th percentile resulted in too few infants to permit meaningful analysis.

Statistical Analysis

Continuous data were described as mean (SD) and categorical data as n (%) as appropriate. Data regarding birthweight were analysed as percentiles. Logistic regression was used to identify the ability of birthweight categories according to different growth standards to predict neonatal categorical outcomes. Unadjusted odds ratios were reported for the associations between birth weight centile category and perinatal outcomes. We used odds ratios instead of risk ratios, as the predictor variable, LGA or SGA, is not a true ‘exposure’ but rather reflects a manifestation of a pathological process which could also be associated with other pregnancy outcomes. We considered that the best performing growth standard to be that which was significantly associated with the most suboptimal perinatal outcomes.

Results

225 women and infants were included in this analysis, including 200 from the pregnancy arm and 25 from the pre-pregnancy arm who became pregnant during the trial. Baseline characteristics and pregnancy outcomes are detailed in Table 1. Most women were over 30 years old (mean age 31.4 years), overweight (mean BMI 25.8 kg/m²), of European or Mediterranean ethnicity (86.2%) and approximately half used insulin pump therapy (48.9%). They had T1D of 16.5 years’ duration with suboptimal glucose control (HbA₁c 6.9%; 51.8 mmol/mol) in early pregnancy as defined by the trial eligibility criteria, which
required HbA$_1$c $\geq$ 6.5% (48 mmol/mol) in early pregnancy. Their infants were born at 37.0 weeks of gestation, predominantly by Caesarean section (68.9%).

Large-for-gestational-age (LGA) rates varied (Table 2. GROW: 62.2%; INTERGROWTH 66.7%; WHO 29.8%) and there were differences in mean centile (Table 1. GROW: 82.1; INTERGROWTH 85.7; WHO 63.9 centiles). Other measures of birth weight are shown in table 2. Other common perinatal complications included neonatal hypoglycaemia (25.3%), hyperbilirubinæmia (27.6%), respiratory distress (8.4%) which all contributed to frequent NICU admissions >24hr (36.9%). Birth injury and shoulder dystocia were uncommon, (1/225 (0.4%) for each) and only occurred in infants who were considered LGA by all criteria. LGA according to GROW, INTERGROWTH and WHO criteria were associated with increased risks of perinatal complications (Table 2). While each growth standard was associated with some complications, no growth standard identified all complications studied. Caesarean section was most strongly associated with LGA, according to all three growth standards. Increased birthweight according to GROW displayed more significant associations with perinatal outcomes than INTERGROWTH (i.e. with preterm delivery, neonatal hypoglycæmia or hyperbilirubinæmia).

Most perinatal complications demonstrated a U-shaped relationship with the birth centile (figure 1). Neonatal hypoglycaemia was most frequent in infants born extremely large for gestational age (ELGA; >97.7$^{th}$ centile). No significant differences in rates of preterm delivery, NICU admission, hyperbilirubinæmia and respiratory distress were observed in smaller infants (<25$^{th}$ centile; figure 1) but there were few infants in this group (Table 2). GROW and INTERGROWTH standards performed similarly and identified similar numbers with LGA (slightly higher for INTERGROWTH) and SGA (slightly higher for GROW). These standards performed consistently regardless of sex, ethnicity and timing of delivery (see supporting tables S1-S3). The positive and negative predictive values of the neonatal outcomes and their associated sensitivity and specificity are varied depending on outcome (supporting table S4). The WHO standards do not take gestational age at birth into account and therefore underestimate size in preterm infants. This resulted in a linear association between WHO centile and preterm delivery (Figure 1).

**Discussion**

This study demonstrates that GROW and INTERGROWTH growth standards perform comparably in type 1 diabetes pregnancy and are both able to identify infants at increased risk of perinatal complications. LGA defined according to GROW centiles (>90$^{th}$ and/or >97.7$^{th}$ centile) showed stronger associations with preterm delivery, neonatal hypoglycaemia, hyperbilirubinæmia and NICU admission.

WHO standards were also able to predict outcomes, but do not incorporate gestational age at delivery, fail to adequately describe size at birth in preterm infants. For term infants, the WHO criteria gave a true birth centile, but for preterm infants, the WHO criteria gave a low centile, which reflected their prematurity, not their comparative size at birth. This measure of prematurity means that the WHO criteria were still able to predict outcomes, despite giving an unreliable birth centile, which demonstrates the importance of preterm delivery in relation to multiple neonatal complications. However, the inability to reliably attribute a
birth weight centile is a substantial limitation in pregnancies of women with T1D, where rates of preterm delivery are high (40% in this study; 46% in clinical data).

As only a small proportion of the antenatal population has T1D diabetes, CONCEPTT represents one of the largest randomised trials with detailed data on perinatal outcomes, making it useful to assess fetal growth, maternal glycaemia and infant risk. Customised (GROW) centiles were reported for CONCEPTT, but the effect of the intervention was also seen using INTERGROWTH standards. Although accelerated fetal growth is common in T1D pregnancies, the rates of LGA in the CONCEPTT infants were higher than expected (66% in CONCEPTT compared to ~46% in a UK population using similar methodology). The reasons for this are unclear, particularly as the CONCEPTT population had better glycaemic control compared to the UK clinical population.

A central aspect to the controversy about GROW and INTERGROWTH centiles involves the perceived importance of maternal factors to the growth of the infant, and ethnicity in particular. A limitation of the CONCEPTT trial is that while it international, 86% of women recruited were of European / Mediterranean origin, which reduced the opportunity to look in depth at growth standard performance in different ethnicities. A further issue is that women who choose to participate in studies are often affluent, well-nourished and educated, and may not represent mothers with different socioeconomic circumstances. Although we have identified that infants <25th centile displayed a trend to be at highest risk of multiple complications, very few infants fall into this category which makes detailed assessment of SGA in diabetic pregnancy very challenging.

The potential value of accurate growth standards is enormous, as identifying LGA or SGA infants offers the opportunity to treat perinatal complications. However, controversy surrounding the performance of different growth standards has been a barrier to improving care. Proponents of the GROW customised approach believe that incorporating maternal variables results in a more accurate representation of size at birth. Conversely, proponents of the INTERGROWTH-21 study state that variables such as ethnicity make little difference to size at birth, in a well-nourished population with access to adequate antenatal care. A major focus for growth standards has been on the identification of infants who are SGA with a view to reducing stillbirth rates.

In this study, standard-deviation-based criteria for the diagnosis of LGA have been assessed. Although a birth weight z score >1 is considered consistent with LGA, this definition is different to standard centile-based definitions (>90th centile). Different approaches to the LGA diagnosis contribute to difficulty in comparing populations internationally.

In this population, the standard definition of SGA identified few infants (1.3-1.8% both with GROW and INTERGROWTH standards). Although SGA is uncommon in type 1 diabetes pregnancy, it is likely than infants born <10th centile do not represent all those with growth restriction. Better understanding of the causes and early identification of growth restriction in diabetic pregnancy should be a research priority.
Larger data sets that examine the risks of this group are required, due to the small numbers in this category examined here.

A fundamental aim of antenatal care in T1D pregnancies involves careful control of maternal factors (e.g. glycaemia) to normalise fetal growth. GROW standards showed stronger associations with neonatal complications but this standard requires additional data to calculate, which may make it less feasible to guide routine care decisions. Significant odds ratios for INTERGROWTH standards were associated with Caesarean delivery, neonatal hypoglycaemia, NICU admission and the composite outcome in the >97.7th centile group. GROW identified fewer infants as LGA compared to INTERGROWTH standards.

WHO growth standards performed poorly here, as there was no adjustment made for infants born preterm. This limitation highlights this system may miss infants at risk, especially those born preterm. Fewer infants identified as LGA using the WHO standards compared to GROW and INTERGROWTH, but those identified were undeniably at high risk of complications. Therefore LGA infants not born near term using WHO standards are at risk of not being identified, giving fewer opportunities for intervention preventing complications.

GROW and INTERGROWTH approach preterm growth differently. GROW centiles are based upon the Hadlock formula for certain gestational ages, suggesting that the growth of preterm and term infants should be exactly the same at any timepoint. The INTERGROWTH standards do not make this assumption but are based on the size of preterm infants at birth. Although this approach seems more scientifically justifiable, as growth abnormalities may contribute to preterm birth, the INTERGROWTH standards were based upon data from real preterm babies, a relatively rare clinical occurrence in a healthy population, there were fewer infants in the very preterm categories which may introduce more uncertainty (details at https://www.intergrowth21.org.uk/protocol.aspx?lang=1 accessed 11/09/2018). More studies in very preterm infants are needed to identify which growth standard might perform best in this group.

Despite maternal diabetes being a risk factor of perinatal morbidity, there has been relatively little assessment of different growth standards in this population. Kase and colleagues reported that customised centiles identified more infants as SGA/LGA compared to population centiles in diabetic pregnancies. Narchi and Skinner had similar findings but concluded there was no evidence of a difference in mortality or morbidity between the infants identified by customised vs population growth standards. The current study adds to the literature by highlighting differences between the common growth standards in a population comparable to clinical populations of women with type 1 diabetes in pregnancy. We had no women with ideal glucose control in early pregnancy (HbA1c<48 mmol/mol) as these women were excluded from the CONCEPTT trial. However, population based studies confirm that only 15% of women with T1D with a HbA1c level <6.5% (48mmol/mol) and thus the data presented here would represent the vast majority of women (85%) with T1D. Future studies should identify optimal growth standard for use even in women with optimal pre-pregnancy Hba1c and in larger cohorts.
Conclusions

WHO growth standards do not incorporate gestational age at birth and therefore are unsuitable for use in diabetic pregnancy, where preterm delivery is commonplace. However, GROW and INTERGROWTH standards are both suitable and GROW showed stronger associations with outcomes. Infants born >97.7th centile had the highest risks of suboptimal perinatal outcomes in this study. Future work should assess if definitions of LGA and SGA should be altered for diabetes pregnancy.

Abbreviations

LGA; large for gestational age, SGA; small for gestational age, CONCEPTT; Continuous Glucose Monitoring in Type 1 Diabetes Pregnancy Trial, NICU; neonatal intensive care unit, T1D; type 1 diabetes, CGM; continuous glucose monitoring, GROW; Gestation Related Optimum Weight, WHO; World Health Organisation, SD; standard deviation, BMI; body mass index.

Declarations

Ethics approval and consent to participate

The CONCEPTT study was approved by the Research Ethics Committee East of England (Essex) under reference 12/EE/0310 in 2012. All participants provided written informed consent. Further ethical approval was not required for this analysis.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

Claire Meek has no relevant conflicts of interest to declare. She currently receives support from the Diabetes UK Harry Keen Intermediate Clinical Fellowship (17/0005712) and the EFSD-Novo Nordisk Foundation Future Leader's Award (NNF19SA058974).

Denice Feig has received honoraria for speaking engagements from Medtronic and has been on an Advisory Board for Novo Nordisk.

Rosa Corcoy has no conflict of interest to declare.

Elizabeth Asztalos (EA) has no conflict of interests to declare.
Laura Kusinski has no conflict of interest to declare.

Esther López has no conflict of interest to declare.

Helen Murphy has received honoraria for speaking engagements from Medtronic, Roche, Novo Nordisk, Eli-Lilly and is a member of the Medtronic European Advisory Board.

CLM is the guarantor of this work and, as such, has had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Funding**

The trial is funded by Juvenile Diabetes Research Foundation (JDRF) grants #17-2011-533, and grants under the JDRF Canadian Clinical Trial Network, a public-private partnership including JDRF and FedDev Ontario and supported by JDRF #80-2010-585. The funders provided solely the finance required for this study and had no role in the trial design, data collection, data analysis or data interpretation. Medtronic supplied the CGM sensors and CGM systems at reduced cost. They also had no role in trial design, collection, handling, analysis or interpretation of data.

HRM conducts independent research supported by the National Institute for Health Research (Career Development Fellowship, CDF-2013-06-035), and is supported by Tommy’s charity. CLM is supported by the Diabetes UK Harry Keen Intermediate Clinical Fellowship (DUK-HKF 17/0005712) and the EFSD-Novonordisk Foundation Future Leader’s Award (NNF19SA058974).

**Authors’ contributions**

CLM designed the study, analysed and interpreted the data, wrote and revised the manuscript. HRM identified the study question, contributed to data analysis, reviewed and revised the manuscript and contributed to the discussion. DSF, EL and RC contributed to study design, data collection, data collation and reviewed and revised the final manuscript. EA and LCK contributed to the discussion and reviewed the final manuscript. All authors gave approval of the final version of the manuscript prior to publication.

**Acknowledgements**

The authors would like to thank all the women with type 1 diabetes who participated in the CONCEPTT trial. We also acknowledge the invaluable support from the 31 clinical care teams and the CONCEPTT Steering Committee: Denice S Feig, Helen R Murphy, Elisabeth Asztalos, Jon F R Barrett, Rosa Corcoy, Alberto de Leiva, Lois E Donovan, J Moshe Hod, Lois Jovanovic, Erin Keely, Craig Kollman, Ruth McManus, Kellie E Murphy, Katrina Ruedy and George Tomlinson.

**References**
1. Weaver LT. In the balance: weighing babies and the birth of the infant welfare clinic. *Bull Hist Med* 2010;84(1):30-57. [published Online First: 2010/07/17]

2. J. C. Observations on Some Causes of the Excess of the Mortality of Males above that of Females. *Philos. Trans. R. Soc. Lond.* 1786.

3. Ray JG, Park AL, Fell DB. Mortality in Infants Affected by Preterm Birth and Severe Small-for-Gestational Age Birth Weight. *Pediatrics* 2017;140(6) doi: 10.1542/peds.2017-1881 [published Online First: 2017/11/10]

4. Doty MS, Chen HY, Sibai BM, et al. Maternal and Neonatal Morbidity Associated With Early Term Delivery of Large-for-Gestational-Age But Nonmacrosomic Neonates. *Obstet Gynecol* 2019;133(6):1160-66. doi: 10.1097/aog.0000000000003285 [published Online First: 2019/05/29]

5. Murphy HR, Bell R, Cartwright C, et al. Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study. *Diabetologia* 2017;60(9):1668-77. doi: 10.1007/s00125-017-4314-3 [published Online First: 2017/06/10]

6. Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTTT): a multicentre international randomised controlled trial. *Lancet* 2017;390(10110):2347-59. doi: 10.1016/S0140-6736(17)32400-5 [published Online First: 2017/09/15]

7. Murphy HR. Continuous glucose monitoring targets in type 1 diabetes pregnancy: every 5% time in range matters. *Diabetologia* 2019;62(7):1123-28. doi: 10.1007/s00125-019-4904-3 [published Online First: 2019/06/05]

8. Gardosi J FA. Gestation network. Customised weight centile calculator. GROW v8.1 UK. [http://www.gestation.net/birthweight_centiles/centile_object.htm](http://www.gestation.net/birthweight_centiles/centile_object.htm)

9. Gardosi J, Claussen B, Francis A. The value of customised centiles in assessing perinatal mortality risk associated with parity and maternal size. *Bjog* 2009;116(10):1356-63. doi: 10.1111/j.1471-0528.2009.02245.x [published Online First: 2009/06/23]

10. Francis A, Hugh O, Gardosi J. Customized vs INTERGROWTH-21(st) standards for the assessment of birthweight and stillbirth risk at term. *Am J Obstet Gynecol* 2018;218(2s):S692-s99. doi: 10.1016/j.ajog.2017.12.013 [published Online First: 2018/02/10]

11. Villar J, Cheikh Ismail L, Victora CG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. *Lancet* 2014;384(9946):857-68. doi: 10.1016/s0140-6736(14)60932-6 [published Online First: 2014/09/12]

12. WHO Child Growth Standards based on length/height, weight and age. *Acta Paediatr Suppl* 2006;450:76-85. [published Online First: 2006/07/05]

13. Papageorghiou AT, Kennedy SH, Salomon LJ, et al. The INTERGROWTH-21(st) fetal growth standards: toward the global integration of pregnancy and pediatric care. *Am J Obstet Gynecol* 2018;218(2s):S630-s40. doi: 10.1016/j.ajog.2018.01.011 [published Online First: 2018/02/10]
14. Anderson NH, Sadler LC, Stewart AW, et al. Maternal and pathological pregnancy characteristics in customised birthweight centiles and identification of at-risk small-for-gestational-age infants: a retrospective cohort study. *BJOG* 2012;119(7):848-56. doi: 10.1111/j.1471-0528.2012.03313.x [published Online First: 2012/04/04]

15. Mackin ST, Nelson SM, Kerssens JJ, et al. Diabetes and pregnancy: national trends over a 15 year period. *Diabetologia* 2018;61(5):1081-88. doi: 10.1007/s00125-017-4529-3

16. Anderson NH, Sadler LC, McKinlay CJD, et al. INTERGROWTH-21st vs customized birthweight standards for identification of perinatal mortality and morbidity. *Am J Obstet Gynecol* 2016;214(4):509.e1-09.e7. doi: 10.1016/j.ajog.2015.10.931 [published Online First: 2015/11/08]

17. Blickstein I, Salihu HM, Keith LG, et al. The association between small-for-gestational age triplet pregnancies and neonatal mortality: a novel approach to growth assessment in multiple gestations. *Pediatr Res* 2006;59(4 Pt 1):565-9. doi: 10.1203/01.pdr.0000202757.47761.76 [published Online First: 2006/03/22]

18. Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic pregnancies: A large, population-based study. *Diabetes Care* 2009;32(11):2005-9. doi: 10.2337/dc09-0656 [published Online First: 2009/08/14]

19. Persson M, Pasupathy D, Hanson U, et al. Birth size distribution in 3,705 infants born to mothers with type 1 diabetes: a population-based study. *Diabetes Care* 2011;34(5):1145-9. doi: 10.2337/dc10-2406 [published Online First: 2011/03/25]

20. Murphy HR, Rayman G, Lewis K, et al. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. *BMJ* 2008;337:a1680. [published Online First: 2008/09/25]

21. Hadlock FP, Harrist RB, Martinez-Poyer J. In utero analysis of fetal growth: a sonographic weight standard. *Radiology* 1991;181(1):129-33. doi: 10.1148/radiology.181.1.1887021

22. Kennedy SH, Altman DG, Purwar M, et al. The intergrowth-21st project: Design, standardisation and quality control strategies. *International Journal of Gynecology and Obstetrics* 2012;119

23. Stefanelli S, Groom KM. The accuracy of ultrasound-estimated fetal weight in extremely preterm infants: a comparison for gestational age and appropriate for gestational age. *Aust N Z J Obstet Gynaecol* 2014;54(2):126-31. doi: 10.1111/ajo.12198 [published Online First: 2014/02/28]

24. Kase BA, Cormier CM, Costantine MM, et al. Population standards of birth weight underestimate fetal growth abnormalities in diabetic pregnancies. *Am J Perinatol* 2012;29(2):147-52. doi: 10.1055/s-0031-1295656 [published Online First: 2011/11/23]

25. Narchi H, Skinner A. Infants of diabetic mothers with abnormal fetal growth missed by standard growth charts. *J Obstet Gynaecol* 2009;29(7):609-13. doi: 10.1080/01443610903100625 [published Online First: 2009/09/17]

**Tables**
Table 1
Maternal Infant Characteristics. BMI: body mass index; GROW: gestation related optimum weight; NICU: neonatal intensive care unit; WHO: World Health Organisation. Composite outcome: birth injury, neonatal hypoglycaemia, hyperbilirubinaemia, respiratory distress syndrome, or neonatal intensive care admission. Diabetes complications defined as any retinopathy, neuropathy or nephropathy.

| Mean (SD) or n (%)                      | n = 225 |
|----------------------------------------|---------|
| **MATERNAL CHARACTERISTICS**           |         |
| Maternal age, years                    | 31.4 (4.5) |
| BMI at enrolment, kg/m²                | 25.8 (4.6) |
| Ethnicity European/ Mediterranean origin | 194 (86.2) |
| Primiparous                            | 89 (39.6) |
| Duration of diabetes, years            | 16.5 (7.7) |
| Diabetes complications                 | 58 (25.8) |
| Hypertension pre-pregnancy             | 15 (6.7) |
| HbA1c at randomisation mmol/mol        | 51.8 (6.6) |
| HbA1c at randomisation %               | 6.9 (0.6)  |
| Smoking                                | 20 (8.9) |
| Insulin pump                           | 110 (48.9) |
| **INFANT CHARACTERISTICS**             |         |
| Sex (% male)                           | 115 (51.1) |
| Gestational age at delivery            | 37.0 (1.6) |
| **BIRTHWEIGHT MEASURES**               |         |
| Birthweight g                          | 3583.6 (705) |
| Macrosomia > = 4 kg                    | 59 (26.2)  |
### Mean (SD) or n (%)

|                         | n = 225 |
|-------------------------|---------|
| GROW centile            | 82.1 (25.9) |
| INTERGROWTH centile     | 85.7 (20.8) |
| WHO centile             | 63.9 (32.0) |

### OBSTETRIC AND PERINATAL OUTCOMES

| Outcome                                           | n     |
|---------------------------------------------------|-------|
| Caesarean section                                 | 155 (68.9) |
| Preterm delivery                                  | 89 (39.6) |
| Neonatal hypoglycaemia requiring intravenous dextrose | 57 (25.3) |
| NICU admission                                    | 83 (36.9) |
| Hyperbilirubinaemia                               | 62 (27.6) |
| Respiratory distress                              | 19 (8.4) |
| Composite neonatal outcome                        | 107 (47.6) |

**Table 2:** Association of adverse neonatal outcomes with low and high birthweights after GROW, INTERGROWTH and WHO criteria. Unadjusted odds ratios and 95% confidence intervals are reported in comparison to all other pregnancies. Neonatal hypoglycaemia included only infants who required IV dextrose. GROW: gestation related optimum weight; NICU: neonatal intensive care unit; WHO: world health organisation. Composite outcome: birth injury, neonatal hypoglycaemia, hyperbilirubinaemia, respiratory distress syndrome, or neonatal intensive care admission. * p < 0.05; ** p < 0.01; *** p < 0.001.
| Birthweight >84.1st centile (mean +1 sd) | n     | Caesarean delivery | Preterm delivery | Neonatal hypoglycaemia | NICU Admission | Hyperbilirubinaemia | Respiratory Distress | Composite Outcome |
|----------------------------------------|-------|--------------------|------------------|------------------------|---------------|---------------------|---------------------|-------------------|
| GROW >84.1st centile                   | 146/225 (64.9%) | 2.31 (1.29 to 4.14)** | 1.11 (0.63 to 1.94) | 1.94 (0.98 to 3.82) | 1.70 (0.94 to 3.05) | 1.81 (0.95 to 3.47) | 2.15 (0.69 to 6.71) | 1.98 (1.13 to 3.47)* |
| INTERGROWTH >84.1st centile           | 167/225 (74.2%) | 2.78 (1.49 to 5.18)*** | 1.10 (0.59 to 2.03) | 1.62 (0.78 to 3.40) | 1.28 (0.68 to 2.40) | 1.27 (0.64 to 2.52) | 1.33 (0.42 to 4.19) | 1.40 (0.77 to 2.56) |
| WHO >84.1st centile                   | 82/225 (36.4%)  | 2.50 (1.32 to 4.76)** | 0.35 (0.19 to 0.63)*** | 1.52 (0.82 to 2.81) | 0.98 (0.56 to 1.72) | 0.70 (0.38 to 1.31) | 0.79 (0.29 to 2.16) | 1.00 (0.58 to 1.72) |

| Birthweight >90th centile (mean +1.28 sd) | n     | Caesarean delivery | Preterm delivery | Neonatal hypoglycaemia | NICU Admission | Hyperbilirubinaemia | Respiratory Distress | Composite Outcome |
|----------------------------------------|-------|--------------------|------------------|------------------------|---------------|---------------------|---------------------|-------------------|
| GROW >90th centile                    | 140/225 (62.2%) | 2.29 (1.28 to 4.08)** | 1.34 (0.76 to 2.33) | 2.25 (1.14 to 4.42)* | 1.85 (1.04 to 3.30)* | 1.89 (1.00 to 3.59)* | 2.43 (0.78 to 7.58) | 2.24 (1.29 to 3.91)** |
| INTERGROWTH >90th centile            | 150/225 (66.7%) | 2.19 (1.22 to 3.95)** | 0.97 (0.55 to 1.71) | 1.98 (0.99 to 3.96) | 1.81 (0.99 to 3.30) | 1.63 (0.85 to 3.13) | 1.97 (0.63 to 6.17) | 1.87 (1.06 to 3.29)* |
| WHO >90th centile                    | 67/225 (29.8%)  | 3.03 (1.47 to 6.25)** | 0.33 (0.17 to 0.63)*** | 1.72 (0.91 to 3.24) | 1.03 (0.57 to 1.85) | 0.76 (0.40 to 1.48) | 0.61 (0.19 to 1.90) | 1.10 (0.62 to 1.95) |

| Birthweight >97.7th centile (mean +2 sd) | n     | Caesarean delivery | Preterm delivery | Neonatal hypoglycaemia | NICU Admission | Hyperbilirubinaemia | Respiratory Distress | Composite Outcome |
|----------------------------------------|-------|--------------------|------------------|------------------------|---------------|---------------------|---------------------|-------------------|
| GROW >97.7th centile                  | 95/225 (42.2%)  | 3.16 (1.68 to 5.93)*** | 1.76 (1.02 to 3.03)* | 3.17 (1.70 to 5.91)*** | 2.18 (1.25 to 3.79)*** | 1.85 (1.03 to 3.35)* | 2.00 (0.77 to 5.17) | 2.22 (1.30 to 3.81)** |
| INTERGROWTH >97.7th centile          | 92/225 (40.9%)  | 2.92 (1.56 to 5.49)*** | 1.13 (0.66 to 1.95) | 3.10 (1.66 to 5.77)*** | 1.88 (1.09 to 3.27)* | 1.27 (0.71 to 2.30) | 1.68 (0.65 to 4.31) | 1.99 (1.16 to 3.41)* |
| WHO >97.7th centile                  | 28/225 (12.4%)  | 1.41 (0.57 to 3.49) | 0.57 (0.24 to 1.36) | 3.58 (1.59 to 8.09)*** | 2.19 (0.98 to 4.87) | 0.86 (0.35 to 2.14) | 1.36 (0.37 to 4.99) | 1.84 (0.82 to 4.12) |

| Birthweight <10th centile (<1.28 sd below mean) | n     | Caesarean delivery | Preterm delivery | Neonatal hypoglycaemia | NICU Admission | Hyperbilirubinaemia | Respiratory Distress | Composite Outcome |
|-----------------------------------------------|-------|--------------------|------------------|------------------------|---------------|---------------------|---------------------|-------------------|
| GROW <10th centile                            | 5/225 (2.2%)   | 1.83 (0.20 to 16.66) | 2.34 (0.38 to 14.28) | 0.73 (0.08 to 6.69) | 2.63 (0.43 to 16.04) | 4.09 (0.67 to 25.11) | 2.81 (0.30 to 26.45) | 1.67 (0.27 to 10.21) |
| INTERGROWTH <10th centile                    | 3/225 (1.3%)   | insufficient events | insufficient events | 3.48 (0.31 to 38.99) | 5.40 (0.48 to 60.65) | 5.67 (0.49 to 65.56) | 2.23 (0.20 to 24.93) | 2.32 (0.19 to 38.48) |
| WHO <10th centile                            | 20/225 (8.9%)  | 1.90 (0.61 to 5.90) | 7.23 (2.33 to 22.44)*** | 1.29 (0.47 to 3.54) | 3.58 (1.37 to 9.38)*** | 2.35 (0.92 to 5.98) | 4.55 (1.44 to 14.34)*** | 3.68 (1.29 to 10.52)* |

| Birthweight <25th centile (<0.675 sd below mean) | n     | Caesarean delivery | Preterm delivery | Neonatal hypoglycaemia | NICU Admission | Hyperbilirubinaemia | Respiratory Distress | Composite Outcome |
|-----------------------------------------------|-------|--------------------|------------------|------------------------|---------------|---------------------|---------------------|-------------------|
| GROW <25th centile                            | 13/225 (5.8%)   | 2.60 (0.56 to 12.04) | 1.85 (0.60 to 5.70) | 0.52 (0.11 to 2.42) | 1.07 (0.34 to 3.40) | 1.70 (0.53 to 5.41) | 2.09 (0.43 to 10.19) | 0.67 (0.21 to 2.13) |
| INTERGROWTH <25th centile                    | 7/225 (3.1%)   | 1.13 (0.21 to 5.99) | 2.09 (0.46 to 9.55) | 0.48 (0.06 to 4.09) | 2.35 (0.51 to 10.75) | 3.68 (0.80 to 16.93) | 4.73 (0.85 to 26.23) | 1.49 (0.33 to 6.81) |
| WHO <25th centile                            | 37/225 (16.4%)  | 1.49 (0.66 to 3.36) | 6.48 (2.88 to 14.57)*** | 1.31 (0.60 to 2.85) | 3.05 (1.48 to 6.30)*** | 2.35 (1.13 to 4.88) | 3.42 (1.25 to 9.39)*** | 3.12 (1.46 to 6.69)*** |
Figures

Figure 1

Rates (%) of caesarean delivery, preterm delivery, neonatal hypoglycaemia, hyperbilirubinaemia, respiratory distress, NICU admission and the composite neonatal outcome according to birth centile
category based on GROW, INTERGROWTH and WHO standards. Numbers in each category are given at the bottom right of this figure.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Supportingmaterial1.5.20.docx
- CONSORT2010Checklist20170731.doc
- SupportinginformationTable406.07.20.docx